ReviewIndian journal of psychological medicine2025
Genetic Insights into Cannabis-induced Psychosis: Role of CNR1 Gene Mutation (rs1049353) and Implications- A Cross-sectional Study.
Review in Indian journal of psychological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Considering the effects of environmental factors and genetic predispositions on mental health outcomes, the current work concentrated on the cannabinoid receptor 1 (CNR1) gene single-nucleotide polymorphism (SNP) rs1049353 as one of the primary genetic markers for cannabis-induced psychosis (CIP). By analyzing this SNP, the study contributes to the corpus of information to identify genetic traits that ultimately predict the response of an evolving disease following exposure to a particular substance after gene and environmental interaction and risk of a particular disease. Methods: Grouped by CIP, cannabis use without psychosis, schizophrenia unlinked to cannabis use, and a healthy control group, a thorough investigation was conducted on a cohort of 120 patients at SCB Medical College, Cuttack. Standardized data collection within a cross-sectional study framework included socio-demographic profiles and genetic tests. Results: Demographic analysis showed no significant differences in education, marital status, religion, occupation, housing, and family type between the groups. Genetic analysis done by real-time polymerase chain reaction (RT-PCR) to detect the prevalence of the CNR1 gene polymorphism among CIP patients was found to be 27.3% (95% CI: 12.1%-42.5%) for the heterogeneous allele and 72.7 % (95% CI: 57.5%-87.9%) for the homogenous allele. CIP patients showed a significant rise in homogenous allele expression in comparison to schizophrenia cases ( Conclusions: The study found that a major contribution to the CIP risk in the CNR1 gene is an SNP, rs1049353. This result helps justify the need to include genetic elements in individual risk of developing a particular disease by linking gene and environmental interaction in cannabis related psychosis and accordingly the treatment plans and public health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.